Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

175.65
+7.814.65%
Post-market: 173.19-2.4600-1.40%19:58 EDT
Volume:2.85M
Turnover:500.58M
Market Cap:23.57B
PE:-50.13
High:179.30
Open:168.25
Low:167.00
Close:167.84
52wk High:179.30
52wk Low:53.40
Shares:134.20M
Float Shares:129.78M
Volume Ratio:2.23
T/O Rate:2.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5037
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-18.07%
PB:-105.77
PE(LYR):-52.90

Loading ...

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live
·
7 hours ago

Movement Alert|Guardant Health Inc. Rises 5.31% in Regular Trading, Shield Blood Test Secures Major New Insurance Coverage Agreement

Market Focus
·
10 hours ago

Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20

Reuters
·
Yesterday

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS
·
Yesterday

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Dow Jones
·
Sep 08

Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live
·
Sep 08

Rothschild & Co Redburn Initiates Guardant Health at Buy

MT Newswires Live
·
Sep 08

Guardant Health initiated with a Buy at Rothschild & Co Redburn

TIPRANKS
·
Sep 08

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

TIPRANKS
·
Sep 05

Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer

THOMSON REUTERS
·
Sep 05

Guardant Health Price Target Maintained with a $195.00/Share by BTIG

Dow Jones
·
Sep 02

Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Guardant Health (GH)

TIPRANKS
·
Sep 02

Guardant Health Shield Blood Test Wins Carelon Coverage for Colorectal Cancer Screening

Reuters
·
Sep 01

Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?

Simply Wall St.
·
Aug 30

Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares

Reuters
·
Aug 25

Guardant Health to Appeal Delaware Court Ruling in Patent Dispute; Shares Fall

MT Newswires Live
·
Aug 25

Guardant Health to appeal federal district court judgment in TwinStrand case

TIPRANKS
·
Aug 25

Guardant Health, Inc.: Remains Confident That it Did not Infringe Asserted Patents

THOMSON REUTERS
·
Aug 25